Cardiff Oncology, Inc. (NASDAQ:CRDF) Position Boosted by Barclays PLC

Barclays PLC lifted its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 291.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,089 shares of the company’s stock after purchasing an additional 39,542 shares during the period. Barclays PLC owned about 0.10% of Cardiff Oncology worth $141,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 DIFC Ltd purchased a new position in Cardiff Oncology in the 2nd quarter worth about $27,000. Dimensional Fund Advisors LP boosted its holdings in shares of Cardiff Oncology by 34.4% in the second quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock worth $42,000 after buying an additional 4,892 shares during the period. SG Americas Securities LLC purchased a new position in shares of Cardiff Oncology in the third quarter worth approximately $64,000. Invst LLC acquired a new stake in shares of Cardiff Oncology during the second quarter valued at approximately $74,000. Finally, American Century Companies Inc. lifted its position in shares of Cardiff Oncology by 98.7% in the 2nd quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock valued at $101,000 after acquiring an additional 22,536 shares in the last quarter. 16.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cardiff Oncology

In other news, Director Gary W. Pace purchased 350,115 shares of Cardiff Oncology stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average cost of $2.60 per share, for a total transaction of $910,299.00. Following the acquisition, the director now directly owns 1,047,876 shares in the company, valued at $2,724,477.60. This represents a 50.18 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on CRDF. Piper Sandler lifted their price objective on shares of Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. HC Wainwright lowered their price target on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, November 8th.

Cardiff Oncology Stock Performance

Shares of CRDF opened at $3.50 on Friday. The company has a market capitalization of $178.96 million, a PE ratio of -3.72 and a beta of 1.76. The company’s 50 day moving average price is $3.46 and its 200 day moving average price is $2.88. Cardiff Oncology, Inc. has a 52 week low of $1.44 and a 52 week high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.13 million. On average, equities analysts forecast that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.